Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial Source: Eur Respir J 2007; 30: Suppl. 51, 240s Year: 2007
Phase II open-label trial of erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
A three-arm phase III randomised trial assessing, in patients with extensive-disease (ED) small-cell lung cancer (SCLC), accelerated chemotherapy with the support of haematological growth factor or of oral antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 319s Year: 2001
Two randomised, double-blind studies of ZD1839 in 425 patients with pretreated advanced non-small-cell lung cancer (IDEAL 1 and IDEAL 2) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002
The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002
A multicenter phase II study of carboplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) in elderly patients (GFPC 9902) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003
Pembrolizumab versus nivolumab as second and further line treatment in non-small cell lung cancer; a retrospective single-centre study Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020
Short-time exercise-induced rehabilitation in non-small cell lung cancer patients during in-hospital chemotherapy treatment: a randomized controlled trial Source: International Congress 2017 – New trends in pulmonary rehabilitation and chronic care Year: 2017
Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003
A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007
Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007
Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
Pemetrexed in the first line treatment in non-small cell lung cancer (NSCLC): A multicentre prospective analysis of data from clinical practise of Czech Republic Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Paclitaxel/carboplatin vs paclitaxel/carboplatin/etoposide as first line treatment in SCLC. A phase III randomized trial Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
LATE-BREAKING ABSTRACT: Triplet chemotherapy (paclitaxel/gemcitabine/cisplatin) is more active in advanced squamous cell subtype (SCC) non-small cell lung cancer (NSCLC) than doublet treatment (vinorelbine/cisplatin): A randomized phase III trial in 443 NSCLC patients Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012
Safety analysis of anti-VEGF therapy bevacizumab (Bv) in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC) in MO19390 (SAiL) trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018
Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003